August 9, 2021

Vannin Capital is backing a class action filed by Phi Finney McDonald against Australian pharmaceutical company Mayne Pharma Group. The proceeding was filed on behalf of current and former shareholders and alleges that Mayne breached its continuous disclosure obligations by, among other things, failing to inform investors about an alleged price-fixing and market-share arrangement in the US. Vannin will take, subject to court approval, a 25% funding commission from a successful outcome.
Lexshares reflects on industry activity in the past few months and shares its surprise at the results of Tets Ishikawa's poll of what users and observers of litigation finance look for most in a funder, noting that in their own experience with funding recipients, pricing is typically much more important than speed and communication, which ranked highest in the poll.
Jeremy Marshall of Omni Bridgeway reviews a recent UK Supreme Court case that centred around an NDA which was signed by a law firm partner who admitted that he hadn’t read it, to the serious detriment of his firm and its litigation funder.
Edward Truant of Slingshot Capital draws on his review of over 1,000 commercial litigation finance case outcomes to explain why litigation finance should not be compared to venture capital and warns investors to be wary of funders whose performance is too dependent on outlier cases.

Before You Go

Never miss a thing in the litigation finance market.